Tempus AI, Inc. Class A ( (TEM) ) has released its Q1 earnings. Here is a breakdown of the information Tempus AI, Inc. Class A presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tempus AI, Inc. is a technology company at the forefront of using artificial intelligence to enhance precision medicine and patient care, primarily operating in the healthcare sector with a focus on genomics and data services.
Tempus AI recently announced its financial results for the first quarter of 2025, showcasing significant growth in revenue and gross profit, alongside strategic partnerships aimed at advancing oncology research.
The company reported a remarkable 75.4% increase in revenue year-over-year, reaching $255.7 million, and a 99.8% rise in gross profit to $155.2 million. Key contributors to this growth include the genomics segment, which saw an 88.9% increase in revenue, and data services, which grew by 43.2%. Tempus also announced strategic collaborations with AstraZeneca and Pathos, expected to generate $200 million in data licensing and model development fees over the next three years.
Despite reporting a net loss of $68 million for the quarter, Tempus improved its adjusted EBITDA by $27.8 million year-over-year. The company also completed the acquisition of Ambry Genetics and Deep 6 AI, expanding its capabilities and market reach.
Looking ahead, Tempus has increased its full-year 2025 revenue guidance to $1.25 billion, representing an 80% growth year-over-year, and anticipates achieving a positive adjusted EBITDA of $5 million, reflecting its strategic focus on leveraging AI to transform diagnostics and drug development.